Health Care Equipment

BRONCUS-B

BRONCUS-B released FY2025 Q3 earnings on March 31, 2026 (BJT), with actual revenue of HKD -5.751M and EPS of HKD -0.0807

BRONCUS-B released FY2025 9 Months Earnings on March 31, 2026 (BJT), with actual revenue of HKD 7.158 M and EPS of HKD -0.2071

BRONCUS-B released FY2025 Q4 earnings on March 31 During-Market (BJT), actual revenue HKD -5.749 M, actual EPS HKD -0.0807

BRONCUS-B released FY2025 annual earnings on March 31 During-Market (BJT), actual revenue HKD 1.357 M (forecast HKD 91.89 M), actual EPS HKD -0.3119 (forecast HKD -0.0784)

BRONCUS-B to release FY2025 earnings on March 31 During-Market (BJT), forecast revenue HKD 91.89 M, EPS HKD -0.0784

BRONCUS-B released FY2025 Q1 earnings on August 28 BJT, actual revenue HKD 6.426 M, actual EPS HKD -0.0629

BRONCUS-B released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue HKD 6.484 M, actual EPS HKD -0.0634

BRONCUS-B released FY2025 Semi-Annual earnings on August 28 During-Market (BJT), actual revenue HKD 12.91 M, actual EPS HKD -0.1264

BRONCUS-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Kunbo Medical's Pulmonary RF Ablation System Approved for Commercialization

Konbio Medical-B shares surge as lung cancer treatment device approved by NMPA

Broncus Medical's Lung Cancer Treatment Device Approved for Market in China

Konbio Medical's BroncAblate® Ablation Device Approved for Market

Kangbo Medical-B to repurchase 161,000 shares for HKD 133,200 on April 7, 2025

BRONCUS-B released FY2024 9 Months Earnings on March 31 (BJT), with actual revenue of 46.16 M HKD and EPS of -0.1855 HKD

BRONCUS-B released FY2024 Q3 earnings on March 31 (BJT) with actual revenue of 17.2 M HKD and EPS of -0.0584 HKD

Kangbo Medical-B (02216) Announces 2024 Performance, Revenue of $8.131 Million, Down 21% Year-on-Year

BRONCUS-B released FY2024 annual earnings on March 31 Pre-Market (BJT), actual revenue 63.37 M HKD (forecast 101.37 M HKD), actual EPS -0.2439 HKD (forecast -0.1564 HKD)

BRONCUS-B released FY2024 Q4 earnings on March 31 Pre-Market (BJT), actual revenue 17.19 M HKD, actual EPS -0.0584 HKD

Kangbo Medical's Lung Imaging Processing Software BroncQCT Approved for Launch by Zhejiang Provincial Drug Administration

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

159883

159898

562600

02216

Broncus Holding Sets Date to Approve 2025 Annual Results and Consider Final Dividend

Tip Ranks

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Broncus Holding Sets Date to Approve 2025 Annual Results and Consider Final Dividend

02500

VENUS MEDTECH-B announced the sale of approximately 1.05% equity in the invested company Valgen Holding to an independent third party, for a cash consideration of USD 15 million, with estimated pre-tax gains from the sale of about USD 800,000. Upon completion, the company will no longer hold any shares in Valgen Holding

AASTOCKS

VENUS MEDTECH-B

VENUS MEDTECH sells minority investment, realizing USD 15 million

01501

BRONCUS-B rose over 9% during the session, and as of the time of writing, it is up 5.86%, priced at HKD 3.25, with a transaction volume of HKD 11.7892 million. In terms of news, BRONCUS announced that it plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, which represents a premium of about 1.3% over the closing price of the previous trading day. The net proceeds are expected to be approximately HKD 327 million, intended for the continued expansion of its product portfolio through potential acquisitions in the medical device industry. The company has been seeking potential acquisition targets in the medical device sector and is currently in communication with various parties. Notably, in this placement, INT MEDICAL plans to invest approximately HKD 283 million to subscribe for about 91.0936 million shares of BRONCUS. The announcement stated that considering BRONCUS's rich product line in the non-vascular interventional field, the subscription could further expand the company's strategic layout in the non-vascular interventional area

Zhitong

INT MEDICAL

Understanding the Market | BRONCUS-B rose over 9% during the session, planning to raise approximately HKD 327 million through a premium placement, with INT MEDICAL subscribing to the majority of the shares

INT MEDICAL announced that it subscribed for a total of 91.0936 million new shares of BRONCUS-B at a total price of HKD 283.3 million, equivalent to a price of HKD 3.11 per share, which is a premium of 1.3% compared to BRONCUS's closing price on the last trading day (10). Upon completion, the company will hold 14.42% of BRONCUS's equity (excluding treasury shares)

INT MEDICAL invested 283 million yuan to acquire 14.42% of BRONCUS-B

Broncus Holding Corp. (HK:2216) announced a proposed share issue of 105,108,015 subscription shares at HK$3.11 each, aiming to raise HK$326.9 million for expansion in the medical devices sector. This represents about 19.90% of its issued share capital. The completion of the subscription is subject to conditions. Analysts currently rate the stock as a Hold with a price target of HK$3.00. Broncus is focused on growth through potential acquisitions in healthcare, with a market cap of HK$1.73B.

Broncus Holding Corp. Announces Share Issue to Fund Expansion

BRONCUS-B plans to issue 105 million subscription shares at a price of HKD 3.11 per share, expecting to raise approximately HKD 327 million in net proceeds, with the subscription price representing a premium of about 1.3% over the market closing price. This issuance will account for approximately 16.60% of the company's issued share capital, and the proceeds will be used for potential acquisitions in the medical device industry to expand the product portfolio

BRONCUS-B plans to issue a total of 105 million subscription shares at a premium of approximately 1.3%, raising a net amount of about HKD 327 million

BRONCUS-B(02216.HK)

Broncus Holding Sets Date to Approve 2025 Annual Results and Consider Final Dividend

VENUS MEDTECH sells minority investment, realizing USD 15 million

Understanding the Market | BRONCUS-B rose over 9% during the session, planning to raise approximately HKD 327 million through a premium placement, with INT MEDICAL subscribing to the majority of the shares

INT MEDICAL invested 283 million yuan to acquire 14.42% of BRONCUS-B

Broncus Holding Corp. Announces Share Issue to Fund Expansion

BRONCUS-B plans to issue a total of 105 million subscription shares at a premium of approximately 1.3%, raising a net amount of about HKD 327 million